Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007759
Filing Date
2025-05-14
Accepted
2025-05-14 16:15:55
Documents
77
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rnaz-20250331x10q.htm   iXBRL 10-Q 1139626
2 EX-31.1 rnaz-20250331xex31d1.htm EX-31.1 16173
3 EX-31.2 rnaz-20250331xex31d2.htm EX-31.2 15754
4 EX-32.1 rnaz-20250331xex32d1.htm EX-32.1 7109
5 EX-32.2 rnaz-20250331xex32d2.htm EX-32.2 6324
  Complete submission text file 0001558370-25-007759.txt   5937788

Data Files

Seq Description Document Type Size
6 EX-101.SCH rnaz-20250331.xsd EX-101.SCH 54957
7 EX-101.CAL rnaz-20250331_cal.xml EX-101.CAL 32466
8 EX-101.DEF rnaz-20250331_def.xml EX-101.DEF 173072
9 EX-101.LAB rnaz-20250331_lab.xml EX-101.LAB 439307
10 EX-101.PRE rnaz-20250331_pre.xml EX-101.PRE 323243
80 EXTRACTED XBRL INSTANCE DOCUMENT rnaz-20250331x10q_htm.xml XML 779932
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40363 | Film No.: 25945758
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)